Table 1: Patient characteristics.

Patient number Gender Age/yrs Weight at start of TCZ Disease Follow up (FU)/mo Indication for TCZ Pred. before TCZ/mg* Pred. at last FU Specifics
1 m 62 77 GCA+PMR 25 toxicity of pretreatment 10 1,5 -
2 f 77 75 GCA+PMR 19 toxicity of pretreatment 5 1 -
3 f 61 62 GCA 4 active vasculitis 7,5 10 Colitis, switch to abatacept
4 f 62 64 LVV+RA 20 active vasculitis 5 7,5 Died in remission after aortic arc replacement
5 m 80 92 GCA+PMR 4 active vasculitis 100 100 Died of E.coli sepsis with sigmoiditis
6 f 66 69 LVV+RA 45 active vasculitis 5 2,5 -
7 f 52 60 GCA+PMR 60 active vasculitis 25 0 -
8 m 78 81 GCA+PMR 17 active vasculitis 17,5 0 -
Switch from TCZ-SC to TCZ-IV due to relapse: Prednisolone reduction
(dose before pulse / dose at last follow-up under TCZ without relapse)
9 f 71 61 GCA 17 active vasculitis 5 20 5 mg / 5mg after 9 mo,
relapse after perioperative stop of TCZ
10 f 47 100 GCA 24 active vasculitis 7,5 3 5 mg / 3 mg after 24 mo
11 f 21 57,5 TAK 20 active vasculitis 17,5 4 15 mg / 4 mg after 20 mo

*In patients with active vasculitis only dose before treatment intensification is given, not a dose of prednisolone pulse.
RA=Rheumatoid Arthritis, GCA=Giant Cell Arteritis, PMR=Polymyalgia Rheumatic, LVV=Large Vessel Vasculitis, TAK=Takayasu Arteritis